avapro and sirolimus
avapro has been researched along with sirolimus in 6 studies
Research
Studies (6)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Daigle, C; Dao, HH; Girardot, D; Martens, FM; Moreau, P; Touyz, RM | 1 |
| Bridle, KR; Campbell, CM; Clouston, AD; Crawford, DH; de Guzman, CE; Jaskowski, LA; Nathan Subramaniam, V; Santrampurwala, N; Sobbe, AL | 1 |
| Alsayed, HA; El-Kherbetawy, MK; Elaidy, SM; Khalil, CM; Mohammad, HMF | 1 |
Reviews
1 review(s) available for avapro and sirolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Other Studies
5 other study(ies) available for avapro and sirolimus
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Signaling of angiotensin II-induced vascular protein synthesis in conduit and resistance arteries in vivo.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Biphenyl Compounds; Blood Pressure; Flavonoids; Irbesartan; Leucine; Male; Mesenteric Arteries; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Biosynthesis; Rats; Rats, Sprague-Dawley; Signal Transduction; Sirolimus; Tetrazoles | 2004 |
Lack of efficacy of mTOR inhibitors and ACE pathway inhibitors as antifibrotic agents in evolving and established fibrosis in Mdr2⁻/⁻ mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Biphenyl Compounds; Captopril; Drug Therapy, Combination; Everolimus; Female; Gene Expression Regulation; Hydroxyproline; Irbesartan; Liver; Liver Cirrhosis, Experimental; Male; Mice, Knockout; Protein Kinase Inhibitors; Renin-Angiotensin System; Signal Transduction; Sirolimus; Species Specificity; Tetrazoles; Time Factors; TOR Serine-Threonine Kinases | 2015 |
Autophagy modulation by irbesartan mitigates the pulmonary fibrotic alterations in bleomycin challenged rats: Comparative study with rapamycin.
Topics: Animals; Autophagy; Bleomycin; Epithelial-Mesenchymal Transition; Irbesartan; Mammals; Pulmonary Fibrosis; Rats; Sirolimus; TOR Serine-Threonine Kinases; Transforming Growth Factor beta1 | 2022 |